Cancer Research at White Plains Hospital | White Plains Hospital

Cancer Research at White Plains Hospital

The Power of Nutrition

Presented by Geralyn Plomitallo MS, RD

Length of presentation: 17:00

The Cancer Program at White Plains Hospital's goal is to always deliver the very best individualized patient care by providing our skilled and dedicated physicians with the newest technologies, techniques and therapies available. Our research program allows White Plains Hospital physicians to offer you the newest and most cutting- edge treatments.

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy (B-43)

This study is being done to compare the effects, good and/or bad, of adding the drug trastuzumab (also called Herceptin) to breast radiation therapy. Radiation therapy is the standard treatment for patients with DCIS. This study will find out if adding trastuzumab to breast radiation therapy is more effective than radiation therapy without trastuzumab in preventing occurrence of breast cancer in the same breast, in the other breast, or in other parts of the body in patients with HER2-positive DCIS.

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer (B-47)

The main purpose of this study is to learn if adding a targeted therapy, trastuzumab (Herceptin), to standard treatment with chemotherapy for early stage, HER2-low breast cancer, will prevent breast cancer from returning. A second purpose of this study is to learn if adding trastuzumab to treatment with chemotherapy will help women with HER2-low breast cancer live longer. Another goal of this study is to find out how the drugs used in this study affect menstrual cycles and if these changes in menstrual cycles have any effect on breast cancer.

EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study (S0931)

The purpose of this study is to see whether treatment with everolimus after surgery for kidney cancer will increase the time without cancer returning. The current standard treatment after surgery is careful monitoring with no immediate treatment. Studies suggest that one way kidney cancer may grow is through chemical signaling through a protein named “mTOR”. Everolimus is a drug that stops signaling through mTOR and may therefore stop the growth of kidney cancer. Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney cancer. It is considered investigational for use after surgery. In this study, patients will get either everolimus or placebo (a pill with no medication).

WFU 97609: Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity

The purpose of this study is to see if the skin reaction you have to radiation therapy is related to substances in your blood and urine. This study is testing to see if genomics have an effect on the disparities in breast cancer radiosensitivity.

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b in Patients with Resected High-Risk Melanoma (E1609)

The purpose of this study is to compare the effects, good and/or bad, of ipilimumab (given at 2 different doses, 10mg/kg or 3 mg/kg) with interferon alfa-2b on patients and their melanoma to find out which is better. In this study, patients will get ipilimumab or the interferon alfa-2b. We plan to determine whether the ipilimumab stops or delays the cancer from returning in comparison to interferon alfa-2b.

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC (E5508)

The purpose of this study is to find out the best maintenance therapy for patients with advanced stage non-small cell lung cancer. Maintenance therapy is usually given after 4 cycles of standard chemotherapy (1 cycle = 21 days) to keep the disease under control for a longer duration. This study will compare the effects, good and/or bad, of bevacizumab, pemetrexed or the combination of the two agents when given as maintenance therapy.

A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less (S1007)

The purpose of this study is to find out if the Oncotype DX® Recurrence Score can help decide whether patients should receive chemotherapy or not. This study is being done in patients with lower Recurrence Scores (25 or less). Currently most women who have hormone receptor positive and HER2 negative breast cancer are treated with endocrine therapy (treatment that works with hormones). Many women also receive chemotherapy. No one really knows which patients with lower Recurrence Scores need to get chemotherapy. If the results of the study show that the benefit for getting chemotherapy is dependent on the Recurrence Score, the study may be able to identify a Recurrence Score level where chemotherapy should be considered (and a recurrence score level where chemotherapy may not be needed).

A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer (RTOG 1005)

This study is for women who have had a lumpectomy to remove cancer from their breast and have been recommended to have radiation therapy. The purpose of this study is to compare radiation therapy given with a higher daily dose over 3 weeks with a boost given each day of radiation therapy compared with standard whole breast radiation followed by a boost given on separate days which extends over 6 to 6 ½ weeks. It is not expected that there would be a difference in survival by changing the number of daily treatments and shortening the length of time needed for treatment. However, shortening treatment length could be more convenient and save time and money. It is not known, but it is hoped, that the higher daily dose of radiation to the breast has the same chance or better of preventing the breast cancer returning compared to standard daily doses of radiation.

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSLC) (E1505)

This research is being done because even with the most aggressive after-surgery treatment with chemotherapy, many people still have the lung cancer recur (come back).

The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure for patients who have had surgery for the removal of the lung cancer. We will compare the effects (good and bad) of adding bevacizumab to chemotherapy with standard chemotherapy alone on you and your lung cancer to see which is better at preventing the cancer from coming back. Bevacizumab is investigational, which means it has not been approved by the FDA for use in this cancer.

A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLC (E1512)

This study is for patients with non-small cell lung cancer. The purpose of this study is to find out what effects, good and/or bad, erlotinib and/or cabozantinib has on you and your lung cancer. Erlotinib is an FDA approved medication. Cabozantinib is an investigational drug, which means that the U.S. Food and Drug Administration (FDA) has not approved it for use in the US except in a research study.

A Phase IIB Clinical Trial of the Anti-Angiogenic Drug Combination TL-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment (TLH206)

The purpose of this study is to see if the investigational combination of drugs called TL-118 (the investigational drugs) given alongside Gemcitabine is effective in treatment of metastatic pancreatic cancer patients, and if people can tolerate taking it without it making them too sick. Investigational (experimental) drugs are drugs that are being tested in people but have not been approved by the U.S. Food and Drug Administration (FDA) for treatment of the studied disease.

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma. (E3A06)

This research study is being done because there is no current therapy proven to benefit patients with high-risk (abnormalities in your blood or bone marrow) asymptomatic myeloma, a type of blood cell cancer that has not yet damaged body tissue and organs to the point where symptoms are noticeable. These patients are not treated unless their disease progresses to symptomatic myeloma. The purpose of this study is to find out what effects (good and bad) the use of the drug lenalidomide has on patients and their multiple myeloma, and to compare this with patients that receive no therapy. Currently, the accepted treatment for asymptomatic myeloma is to receive no therapy.